Precision medicine for acute pancreatitis: current status and future opportunities

Acute pancreatitis is a common inflammatory condition affecting the pancreas, predominantly caused by gallstones, alcohol excess, and hypertriglyceridaemia, with severe disease carrying up to 50% mortality. Despite significant research and preclinical promise, no targeted drug treatments exist for t...

Full description

Saved in:
Bibliographic Details
Published in:Precision clinical medicine 2019-06, Vol.2 (2), p.81-86
Main Authors: Mukherjee, Rajarshi, Nunes, Quentin, Huang, Wei, Sutton, Robert
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c387t-ffe28e235e40bd15ef05749772e4f7567af6617057257df328c2d13e9fb020143
cites cdi_FETCH-LOGICAL-c387t-ffe28e235e40bd15ef05749772e4f7567af6617057257df328c2d13e9fb020143
container_end_page 86
container_issue 2
container_start_page 81
container_title Precision clinical medicine
container_volume 2
creator Mukherjee, Rajarshi
Nunes, Quentin
Huang, Wei
Sutton, Robert
description Acute pancreatitis is a common inflammatory condition affecting the pancreas, predominantly caused by gallstones, alcohol excess, and hypertriglyceridaemia, with severe disease carrying up to 50% mortality. Despite significant research and preclinical promise, no targeted drug treatments exist for the disease and precision medicine approaches are lacking significantly, when compared to other health conditions. Advances in omics applications will facilitate improved preclinical models and target identification as well as biomarker discovery for refined trial design, focusing on risk stratification, subject selection, and outcome determination. Randomised treatment of Acute Pancreatitis with Infliximab: Double-blind, placebo-controlled, multi-centre trial (RAPID-I) is a pioneering trial, currently under way in acute pancreatitis, which may serve as an innovative model for the implementation of precision medicine strategies for acute pancreatitis in the future.
doi_str_mv 10.1093/pcmedi/pbz010
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8985768</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2675987013</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-ffe28e235e40bd15ef05749772e4f7567af6617057257df328c2d13e9fb020143</originalsourceid><addsrcrecordid>eNpVkctLAzEQxoMoKtWjV8nRy9o8N7seBBFfUFBEzyHNTjTSbtY8BP3rXWmVepph5sc3H_MhdETJKSUtnw52CZ2fDvMvQskW2meS1hWVim5v9HvoMKU3QgijQoiG7KI9LuuWCdHuo8eHCNYnH3r8I2V9D9iFiI0tGfBgehvBZJ99OsO2xAh9ximbXBI2fYddySUCDsMQYi79yEE6QDvOLBIcrusEPV9fPV3eVrP7m7vLi1lleaNy5RywBhiXIMi8oxIckUq0SjEQTslaGVfXVI1DJlXnOGss6yiH1s0JI1TwCTpf6Q5lPnq3o7VoFnqIfmnipw7G6_-b3r_ql_Chm7aRqm5GgZO1QAzvBVLWS58sLBamh1CSZrWSbaMI5SNarVAbQ0oR3N8ZSvRPFHoVhV5FMfLHm97-6N_H82-y8ojA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2675987013</pqid></control><display><type>article</type><title>Precision medicine for acute pancreatitis: current status and future opportunities</title><source>Open Access: PubMed Central</source><source>Oxford University Press Open Access</source><creator>Mukherjee, Rajarshi ; Nunes, Quentin ; Huang, Wei ; Sutton, Robert</creator><creatorcontrib>Mukherjee, Rajarshi ; Nunes, Quentin ; Huang, Wei ; Sutton, Robert</creatorcontrib><description>Acute pancreatitis is a common inflammatory condition affecting the pancreas, predominantly caused by gallstones, alcohol excess, and hypertriglyceridaemia, with severe disease carrying up to 50% mortality. Despite significant research and preclinical promise, no targeted drug treatments exist for the disease and precision medicine approaches are lacking significantly, when compared to other health conditions. Advances in omics applications will facilitate improved preclinical models and target identification as well as biomarker discovery for refined trial design, focusing on risk stratification, subject selection, and outcome determination. Randomised treatment of Acute Pancreatitis with Infliximab: Double-blind, placebo-controlled, multi-centre trial (RAPID-I) is a pioneering trial, currently under way in acute pancreatitis, which may serve as an innovative model for the implementation of precision medicine strategies for acute pancreatitis in the future.</description><identifier>ISSN: 2516-1571</identifier><identifier>ISSN: 2096-5303</identifier><identifier>EISSN: 2516-1571</identifier><identifier>DOI: 10.1093/pcmedi/pbz010</identifier><identifier>PMID: 35692449</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><ispartof>Precision clinical medicine, 2019-06, Vol.2 (2), p.81-86</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of International Communication Association.</rights><rights>The Author(s) 2019. Published by Oxford University Press on behalf of International Communication Association. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-ffe28e235e40bd15ef05749772e4f7567af6617057257df328c2d13e9fb020143</citedby><cites>FETCH-LOGICAL-c387t-ffe28e235e40bd15ef05749772e4f7567af6617057257df328c2d13e9fb020143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985768/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985768/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35692449$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mukherjee, Rajarshi</creatorcontrib><creatorcontrib>Nunes, Quentin</creatorcontrib><creatorcontrib>Huang, Wei</creatorcontrib><creatorcontrib>Sutton, Robert</creatorcontrib><title>Precision medicine for acute pancreatitis: current status and future opportunities</title><title>Precision clinical medicine</title><addtitle>Precis Clin Med</addtitle><description>Acute pancreatitis is a common inflammatory condition affecting the pancreas, predominantly caused by gallstones, alcohol excess, and hypertriglyceridaemia, with severe disease carrying up to 50% mortality. Despite significant research and preclinical promise, no targeted drug treatments exist for the disease and precision medicine approaches are lacking significantly, when compared to other health conditions. Advances in omics applications will facilitate improved preclinical models and target identification as well as biomarker discovery for refined trial design, focusing on risk stratification, subject selection, and outcome determination. Randomised treatment of Acute Pancreatitis with Infliximab: Double-blind, placebo-controlled, multi-centre trial (RAPID-I) is a pioneering trial, currently under way in acute pancreatitis, which may serve as an innovative model for the implementation of precision medicine strategies for acute pancreatitis in the future.</description><issn>2516-1571</issn><issn>2096-5303</issn><issn>2516-1571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkctLAzEQxoMoKtWjV8nRy9o8N7seBBFfUFBEzyHNTjTSbtY8BP3rXWmVepph5sc3H_MhdETJKSUtnw52CZ2fDvMvQskW2meS1hWVim5v9HvoMKU3QgijQoiG7KI9LuuWCdHuo8eHCNYnH3r8I2V9D9iFiI0tGfBgehvBZJ99OsO2xAh9ximbXBI2fYddySUCDsMQYi79yEE6QDvOLBIcrusEPV9fPV3eVrP7m7vLi1lleaNy5RywBhiXIMi8oxIckUq0SjEQTslaGVfXVI1DJlXnOGss6yiH1s0JI1TwCTpf6Q5lPnq3o7VoFnqIfmnipw7G6_-b3r_ql_Chm7aRqm5GgZO1QAzvBVLWS58sLBamh1CSZrWSbaMI5SNarVAbQ0oR3N8ZSvRPFHoVhV5FMfLHm97-6N_H82-y8ojA</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Mukherjee, Rajarshi</creator><creator>Nunes, Quentin</creator><creator>Huang, Wei</creator><creator>Sutton, Robert</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190601</creationdate><title>Precision medicine for acute pancreatitis: current status and future opportunities</title><author>Mukherjee, Rajarshi ; Nunes, Quentin ; Huang, Wei ; Sutton, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-ffe28e235e40bd15ef05749772e4f7567af6617057257df328c2d13e9fb020143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mukherjee, Rajarshi</creatorcontrib><creatorcontrib>Nunes, Quentin</creatorcontrib><creatorcontrib>Huang, Wei</creatorcontrib><creatorcontrib>Sutton, Robert</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Precision clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mukherjee, Rajarshi</au><au>Nunes, Quentin</au><au>Huang, Wei</au><au>Sutton, Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Precision medicine for acute pancreatitis: current status and future opportunities</atitle><jtitle>Precision clinical medicine</jtitle><addtitle>Precis Clin Med</addtitle><date>2019-06-01</date><risdate>2019</risdate><volume>2</volume><issue>2</issue><spage>81</spage><epage>86</epage><pages>81-86</pages><issn>2516-1571</issn><issn>2096-5303</issn><eissn>2516-1571</eissn><abstract>Acute pancreatitis is a common inflammatory condition affecting the pancreas, predominantly caused by gallstones, alcohol excess, and hypertriglyceridaemia, with severe disease carrying up to 50% mortality. Despite significant research and preclinical promise, no targeted drug treatments exist for the disease and precision medicine approaches are lacking significantly, when compared to other health conditions. Advances in omics applications will facilitate improved preclinical models and target identification as well as biomarker discovery for refined trial design, focusing on risk stratification, subject selection, and outcome determination. Randomised treatment of Acute Pancreatitis with Infliximab: Double-blind, placebo-controlled, multi-centre trial (RAPID-I) is a pioneering trial, currently under way in acute pancreatitis, which may serve as an innovative model for the implementation of precision medicine strategies for acute pancreatitis in the future.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>35692449</pmid><doi>10.1093/pcmedi/pbz010</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2516-1571
ispartof Precision clinical medicine, 2019-06, Vol.2 (2), p.81-86
issn 2516-1571
2096-5303
2516-1571
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8985768
source Open Access: PubMed Central; Oxford University Press Open Access
title Precision medicine for acute pancreatitis: current status and future opportunities
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T00%3A36%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Precision%20medicine%20for%20acute%20pancreatitis:%20current%20status%20and%20future%20opportunities&rft.jtitle=Precision%20clinical%20medicine&rft.au=Mukherjee,%20Rajarshi&rft.date=2019-06-01&rft.volume=2&rft.issue=2&rft.spage=81&rft.epage=86&rft.pages=81-86&rft.issn=2516-1571&rft.eissn=2516-1571&rft_id=info:doi/10.1093/pcmedi/pbz010&rft_dat=%3Cproquest_pubme%3E2675987013%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c387t-ffe28e235e40bd15ef05749772e4f7567af6617057257df328c2d13e9fb020143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2675987013&rft_id=info:pmid/35692449&rfr_iscdi=true